
SOTS 2nd Hour: Novo Nordisk Oral Weight-Loss Pill, Global Market Outlook, “Aggressive Housing Reform” 12/23/25
Squawk on the Street
00:00
Novo Nordisk's Oral GLP-1 Approval
Annika previews the FDA approval and sets up the CEO interview about Wagovi pill's access and pricing.
Play episode from 16:49
Transcript


